Evolving Personalized Therapy for Castration-Resistant Prostate Cancer

With advances in molecular biologic and genomic technology, detailed molecular mechanisms for development of castration-resistant prostate cancer (CRPC) have surfaced. Metastatic prostate cancer (PCa) no longer represents an end stage, with many emerging therapeutic agents approved as effective in p...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Hsin-Ho, Tsai, Yuh-Shyan, Lai, Chen-Li, Tang, Chih-Hsin, Lai, Chih-Ho, Wu, Hsi-Chin, Hsieh, Jer-Tsong, Yang, Che-Rei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: China Medical University 2014
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264971/
https://www.ncbi.nlm.nih.gov/pubmed/25520915
http://dx.doi.org/10.7603/s40681-014-0002-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264971/
https://www.ncbi.nlm.nih.gov/pubmed/25520915
http://dx.doi.org/10.7603/s40681-014-0002-5

Ejemplares similares